← VisionSys AI Inc (VSA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
VisionSys AI Inc (VSA)
Services-Educational Services · market cap $6M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
VisionSys AI Inc (VSA) is a ~$250M market-cap company classified under educational services with 3,854 employees, yet its disclosed lead asset is Rebamipide 2% ophthalmic suspension in Phase 3 for Dry Eye Syndrome. No recent or upcoming catalysts are on the calendar, no financial detail (cash, runway, revenue) has been provided, and zero analyst coverage exists.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Rebamipide 2% ophthalmic suspension | Phase 3 | Dry Eye Syndrome |
Price & technical context
3-month
-47.1%
6-month
-63.2%
12-month
-98.6%
52-wk range
$0.83–$172.00
vs 50-day MA
-28.9%
vs 200-day MA
-43.2%
Realized vol
342.8%
Max drawdown
-99.6%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VSA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.